MR 1 TONE WHITE

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Complete if Known						
									/810,578			
									eptember 14, 2001			
						First Named Inventor EL			ELDAR-FINKELMAN .			
)IA	LIVIENT BI AFF	LICANI					1645				
	(1	ise as many sheets as ned	cessary)		Examiner Name				-			
Sheet	Ť	1	of	a	Attorne	y Docket N	umber	27457				
5.1000		<u> </u>		PATENT					Class /Juliclass			
Examiner Initials*	Cite No. 1	Document Number Publication		Date		Name of Patent	lame of Patentee or		Pages, Columns, Lines, Where Relevant			
			MM-DD-Y	YYY	Applicant of Cited Document		Document	Passages or Redoca		Appear		
		Number-Kind Code ^{2 (if known)}										
M	1	US-6,153,618	11-28-2000			Schultz et	al.		514/261			
321	2	US-6,057,117	02-2-2000			Harrison et al.			43517.93	-		
0,												
		· · · · · · · · · · · · · · · · · · ·	ļ <u></u>									
						-4						
									-			
					, , , , , , , , , , , , , , , , , , , ,							


			FOREIG	N PATE	ENT DO	CUMENTS			C(=25/5/06/-2)			
Examiner	Cite								Pages, Columns, Lines			
Initials*	No. 1	Foreign Patent Docu	Publicat MM-DI			Name of Patentee or licant of Cited Document		Where Relevant Passages	ages T°			
		Country Code ³ Number ⁴ Kind Code ³ (if known)						or Relevant Figures Appear				
	3	PCT WO 98/16528		04-23-		Schultz et al.						
BL	4	PCT WO 01/49709		07-12-2001 03-28-2002 05-5-2000		Eldar-Finkleman Biondi et al. Mendlovic et al.						
18-80	5	PCT WO 02/24941										
YW	6	PCT WO 00/59206										
Jage.	7	PCT WO 00/45237	T WO 00/45237		03-3-2000		Cohen-Or et al.					
X	8	PCT WO 00/74663		12-14-2000		Rosenthal et al.						
<u> </u>												
				ļ								
		<u> </u>		L		l			<u> </u>			
Examine		Jeffrey E. Russel				Date			At A			
Signature		VETTE CIL	W15:01				Consider	ed	November 14,200	5		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Approved for use through 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPAR
Under the Paperwork Reduction Act of 1995, the required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwor		Act of 1995	to respond to a con	icetion of thornation an	icas ir comunis	Complete	if Kno	wn			
	Su	stitute for form 1449A/PTO	Application Number			10/810,578					
	INF	DRMATION DISC	Filing Date		Sept	September 14, 2001					
		TEMENT BY AP	First Named Inventor		ELDAR- FINKELMAN						
		use as many sheets as ne	cessary)		Group A	rt Unit	1645	5			
		······································	,,		Examine	r Name	1				
Sheet	2	Of		2	Attorney	Docket Number	2745	57			
	1	OTHER PRIOR	ART - NON	PATENT LITER	ATURE I	OCUMENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the									
Initials	No.	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	9	9 Eldar-Finkleman et al. "The Insulin Mimetic Action of Glycogen Synthase Kinase-3									
741		Inhibitors", Diabetologia, 45(Suppl.2): A 70, 38th Annual Meeting for the European									
	ļ.,	Association for the Study of Diabetes (EASD), Budapest, Hungary, 2002. Abstract.									
(X)	10	Plotkin et al. "Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors"									
MA			Synthase Kinase-3", Journal of Pharmacology and Experimental								
<u> </u>	-	Therapeutics, 305(3): 974-980, 2003.									
\ . I	11	Leclerc et al. "Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two									
$M \setminus$	į	Proteins Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's									
<u> </u>	1.2	Disease", The Journal of Biological Chemistry, 276(1): 251-260, 2001.									
101	12	Hotamisligil et al. "IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase									
X40		Activity in TNT-α- and Obesity-Induced Insulin Resistance", Science, 271: 665-, 1996.									
	1,2		i Dhh	andation of Insul	lin Dagant	on Cubetnete 1		 			
\sqrt{n}	13	Tanti et al. "Serine/Threonine Phosphorylation of Insulin Receptor Substrate 1 Modulates Insulin Receptor Signaling", The Journal of Biological Chemistry, 269(8):									
140		6051-6057, 1994.	ai Chemisuy, 2	U9(8).							
	14		Inhibition of PRB Phosphorylation and Cell-Cycle Progression by a								
The A		20-Residue Peptide Der	ne Peptide Derived from P16 CDKN2/INK4A", Current Biology, 6(1): 84-								
	ļ	91, 1996.									
	15	Mitchell et al. "Heat Stable Inhibitor Protein Derived Peptide Substrate Analogs:									
]	Phosphorylation by a	m p-Dependen	t-and-eGMP-Dep	endent Pro	otein-Kinases",	Am.	4			
		Chemical Soc., 1994.		<u> </u>							
D-1	16	Maniatis "Signal Transduction: Catalysis by a Multiprotein IkB Kinase Complex",									
		Science, 278(5339): 818, 1997. Extract.									
VX21	27	American Diabetes Association "Standards of Medical Care for Patients With									
1111		Diabetes Mellitus", Dia									
Hawiger, J., "Non-Invasive Intracellular Delivery of Functional Peptides", Curr. Opin. Chem. Biol., 3:89-94, 1999											
U.	 	Орин Сион. Бюл, 3.07-74, 1777									
	 										
	!			<u> </u>		- '*'					
	 	<u>L</u>		· · · · · · · · · · · · · · · · · · ·				1			
Signature	700	Fren E. Russel				Considered		November 14, 2005			
Dignature	<u> </u>	THEY IS I WOULD		····		Constacted		Indicard (" son			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is unique citation designation number (optional).

3. Applicant is unique citation designation number (optional).

3. Applicant is unique citation designation is attached.

This collection of information is required by 37 CFR 1.97, and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.